« Απάντηση #66 στις: Ιουλίου 21, 2018, 08:44:18 »
O FDA παραδέχεται πως το Gardasil Eμβόλιο, για το hpv, προκαλεί θανάτους, εξακριβωμένα, και συνεχίζουν και το σπρώχνουν στα παιδιά μας...
https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
Serious Adverse Reactions in the Entire Study Population
Across the clinical studies, 258 individuals (GARDASIL N = 128 or 0.8%; placebo N = 130 or 1.0%) out
of 29,323 (GARDASIL N = 15,706; AAHS control N = 13,023; or saline placebo N = 594) individuals (9-
through 45-year-old girls and women; and 9- through 26-year-old boys and men) reported a serious
systemic adverse reaction.
Of the entire study population (29,323 individuals), 0.04% of the reported serious systemic adverse
reactions were judged to be vaccine related by the study investigator. The most frequently (frequency of 4
cases or greater with either GARDASIL, AAHS control, saline placebo, or the total of all three) reported
serious systemic adverse reactions, regardless of causality, were:
Headache [0.02% GARDASIL (3 cases) vs. 0.02% AAHS control (2 cases)],
Gastroenteritis [0.02% GARDASIL (3 cases) vs. 0.02% AAHS control (2 cases)],
Appendicitis [0.03% GARDASIL (5 cases) vs. 0.01% AAHS control (1 case)],
Pelvic inflammatory disease [0.02% GARDASIL (3 cases) vs. 0.03% AAHS control (4 cases)],
Urinary tract infection [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (2 cases)],
Pneumonia [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (2 cases)],
Pyelonephritis [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (3 cases)],
Pulmonary embolism [0.01% GARDASIL (2 cases) vs. 0.02% AAHS control (2 cases)].
One case (0.006% GARDASIL; 0.0% AAHS control or saline placebo) of bronchospasm; and 2 cases
(0.01% GARDASIL; 0.0% AAHS control or saline placebo) of asthma were reported as serious systemic
adverse reactions that occurred following any vaccination visit.
In addition, there was 1 individual in the clinical trials, in the group that received GARDASIL, who
reported two injection-site serious adverse reactions (injection-site pain and injection-site joint movement
impairment).
Deaths in the Entire Study Population
Across the clinical studies, 40 deaths (GARDASIL N = 21 or 0.1%; placebo N = 19 or 0.1%) were
reported in 29,323 (GARDASIL N = 15,706; AAHS control N = 13,023, saline placebo N = 594) individuals
(9- through 45-year-old girls and women; and 9- through 26-year-old boys and men). The events reported
were consistent with events expected in healthy adolescent and adult populations. The most common
cause of death was motor vehicle accident (5 individuals who received GARDASIL and 4 individuals who
received AAHS control), followed by drug overdose/suicide (2 individuals who received GARDASIL and 6
individuals who received AAHS control), gunshot wound (1 individual who received GARDASIL and 3
individuals who received AAHS control), and pulmonary embolus/deep vein thrombosis (1 individual who
8
received GARDASIL and 1 individual who received AAHS control). In addition, there were 2 cases of
sepsis, 1 case of pancreatic cancer, 1 case of arrhythmia, 1 case of pulmonary tuberculosis, 1 case of
hyperthyroidism, 1 case of post-operative pulmonary embolism and acute renal failure, 1 case of traumatic
brain injury/cardiac arrest, 1 case of systemic lupus erythematosus, 1 case of cerebrovascular accident, 1
case of breast cancer, and 1 case of nasopharyngeal cancer in the group that received GARDASIL; 1
case of asphyxia, 1 case of acute lymphocytic leukemia, 1 case of chemical poisoning, and 1 case of
myocardial ischemia in the AAHS control group; and 1 case of medulloblastoma in the saline placebo
group.
« Τελευταία τροποποίηση: Ιουλίου 21, 2018, 08:47:50 από Rose »
Καταγράφηκε